China NMPA Drug Inspection - Jilin Xianfeng Technology Pharmaceutical Co., Ltd. - Erythromycin stearate capsules
China NMPA drug inspection for Jilin Xianfeng Technology Pharmaceutical Co., Ltd. published June 15, 2018. Drug: Erythromycin stearate capsules. On June 15, 2018, the National Medical Products Administration (NMPA) of China announced that 11 batches of drugs from e
One-time purchase from the GKS catalog. Lifetime access in your library. Single documents and full company profiles available. All sales final.
China NMPA drug inspection for Jilin Xianfeng Technology Pharmaceutical Co., Ltd. published June 15, 2018. Drug: Erythromycin stearate capsules. On June 15, 2018, the National Medical Products Administration (NMPA) of China announced that 11 batches of drugs from e
Access our comprehensive regulatory intelligence platform to analyze patterns, track compliance trends, and stay ahead of regulatory changes.
Transform Regulatory Data into Actionable Intelligence
Join leading pharmaceutical and medical device companies who trust GKS for their regulatory compliance needs.
Try KeyPedia Today
Explore our real use cases and discover our features in depth.
Subscribe to our newsletter
Get the latest updates and insights delivered to your inbox